Company: ARWR
Filing Date: 2025-12-11
Form Type: S-3ASR
Source: 0001193125-25-314755
Chunk: 43

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-12-11
Form: S-3ASR
Chunk 43
---
 unlawful dividends or unlawful stock repurchases or redemptions or (iv) transactions in which the director received an improper personal benefit. Section 145 of the DGCL permits a Delaware corporation to indemnify, on certain terms and conditions, any person who was or is a party or is threatened to be made a party to any threatened pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action. The Certificate of Incorporation and Bylaws of the Company require the Company to indemnify the Company’s directors and officers to the fullest extent permitted under Delaware law. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, the Company has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. II-1

Item 16. Exhibit Index. The following documents are filed herewith (unless otherwise indicated) and made a part of this registration statement.

| Exhibit 
 NO.     
 1.1     
 1.2     
 3.1     |     | Description                                                                                                                                     
 Form of Underwriting Agreement*                                                                                                                 
 Amended and Restated Open Market Sale Agreement, dated December 10, 2025, by and between Arrowhead Pharmaceuticals, Inc. and Jefferies LLC.     
 Amended and Restated Certificate of Incorporation of Arrowhead Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.3 to the Company’s 
 Current Report on Form 8-K, filed on April 6, 2016)                                                                                             |
|:--------|:----|:------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.2     |     | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Arrowhead Pharmaceuticals, Inc. (incorporated              
 by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q, filed on May 2, 2023).                                              |
| 3.3     |     | Second Amended and